Last $0.13 USD
Change Today +0.0145 / 13.12%
Volume 104.4K
AEMD On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

aethlon medical inc (AEMD) Snapshot

Open
$0.11
Previous Close
$0.11
Day High
$0.13
Day Low
$0.11
52 Week High
03/12/14 - $0.27
52 Week Low
08/26/14 - $0.11
Market Cap
32.6M
Average Volume 10 Days
242.8K
EPS TTM
$-0.04
Shares Outstanding
261.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AETHLON MEDICAL INC (AEMD)

Related News

No related news articles were found.

aethlon medical inc (AEMD) Related Businessweek News

No Related Businessweek News Found

aethlon medical inc (AEMD) Details

Aethlon Medical, Inc., a medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company’s Aethlon Hemopurifier is intended for the treatment of antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It also develops exosome-based products to diagnose and monitor cancer, infectious diseases, and neurological disorders; and is developing a medical device to reduce the incidence of sepsis in combat-injured soldiers. The company was founded in 1991 and is based in San Diego, California.

10 Employees
Last Reported Date: 07/15/14
Founded in 1991

aethlon medical inc (AEMD) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $400.0K
President and Director
Total Annual Compensation: $240.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $183.0K
Chief Scientific Officer, Vice President and ...
Total Annual Compensation: $195.0K
Compensation as of Fiscal Year 2014.

aethlon medical inc (AEMD) Key Developments

Aethlon Medical, Inc. announced delayed annual 10-K filing

On 06/30/2014, Aethlon Medical, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Aethlon Medical, Inc. Presents at 25th Annual WSAF Institutional Investor Conference, Jun-19-2014 12:05 PM

Aethlon Medical, Inc. Presents at 25th Annual WSAF Institutional Investor Conference, Jun-19-2014 12:05 PM. Venue: The University Club, 1 W. 54th Street, New York, NY 10019, United States. Speakers: Jim Joyce, Chairman and Chief Executive Officer.

Aethlon Medical Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients

Aethlon Medical, Inc. announced high rapid virologic response (RVR) and sustained virologic response (SVR) rates in Hepatitis-C virus (HCV) infected individuals who were administered Hemopurifier(R) therapy. The Aethlon Hemopurifier(R) is a first-in-class medical device that selectively targets the rapid clearance of viral pathogens and tumor-secreted exosomes from the entire circulatory system to improve the benefit of drug therapies administered to infectious disease and cancer patients. In HCV care, the device is positioned to address drug resistance associated with emerging all-antiviral therapies and also targets to accelerate HCV RNA depletion at the outset of peginterferon+ribavirin (PR) therapy. Aethlon recently disclosed that the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) that now allows the Company to initiate HCV human feasibility studies of Hemopurifier(R) therapy in the United States. Aethlon announced May 20, 2014 that its first U.S. clinical study will be conducted at the DaVita MedCenter Dialysis in Houston, Texas. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation. In the reported study, HCV-infected individuals were enrolled to receive three six-hour Hemopurifier(R) treatments during the first three days of a 48-week peginterferon+ribavirin (PR) treatment regimen. The study was conducted under the leadership of Dr. Vijay Kher at the Medanta Medicity, a multi-specialty medical institute established to be a premier center for medical tourism in India. Aethlon reported that Hemopurifier(R) therapy was well tolerated and without device-related adverse events in twelve treated patients. Of these twelve patients, nine completed the Hemopurifier-PR treatment protocol, including seven genotype-1 patients and two genotype-3 patients. Seven of the nine patients (n=7/9) achieved a sustained virologic response (SVR), which is the clinical definition of treatment cure and is defined as undetectable HCV RNA 24-weeks after the completion of the 48-week PR drug regimen. Both genotype-3 patients achieved a SVR (n=2/2), while five of the seven genotype-1 patients achieved a SVR (n=5/7). Of the nine patients that completed the protocol, five (n=5/9) also achieved a rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts SVR cure rates. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only 10.35% (n=318/3070) of PR treated patients will achieve a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. Data from three patients were not included in the reported dataset. Among the three patients was a genotype-5 patient who discontinued PR therapy at day 180, yet remained undetectable at 1.5 years after initiation of therapy. The second was a genotype-3 patient who was unable to tolerate PR therapy and, as a result, discontinued PR therapy at day-90, yet was still undetectable one year after initiating therapy. The third patient, who had the genotype-1 virus, was reported undetectable at the completion of the 48-week PR treatment regimen, but SVR results are not due on that patient until September of this year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEMD:US $0.13 USD +0.0145

AEMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEMD.
View Industry Companies
 

Industry Analysis

AEMD

Industry Average

Valuation AEMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETHLON MEDICAL INC, please visit www.aethlonmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.